Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation

Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation

Aim: This study aimed to evaluate the safety and efficacy profile of low-dose tocilizumab (TCZ), to prevent disease progression, subcutaneously administered to patients with moderate COVID-19 pneumonia and hyperinflammation. Methods: Clinical characteristics and outcomes were retrospectively analyse...

Full description

Bibliographic Details
Main Authors: Nicola Potere, Marcello Di Nisio, Giulia Rizzo, Matteo La Vella, Ennio Polilli, Adriana Agostinone, Antonella Spacone, Silvio Di Carlo, Alberto Costantini, Antonio Abbate, Ettore Porreca, Giustino Parruti
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
SARS-CoV-2
Inflammation
Cytokine release syndrome
IL-6
Tocilizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220306160

Internet

http://www.sciencedirect.com/science/article/pii/S1201971220306160

Similar Items